These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 18464107)
1. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Roussou M; Kastritis E; Migkou M; Psimenou E; Grapsa I; Matsouka C; Barmparousi D; Terpos E; Dimopoulos MA Leuk Lymphoma; 2008 May; 49(5):890-5. PubMed ID: 18464107 [TBL] [Abstract][Full Text] [Related]
2. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061 [TBL] [Abstract][Full Text] [Related]
4. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Malani AK; Gupta V; Rangineni R Acta Haematol; 2006; 116(4):255-8. PubMed ID: 17119326 [TBL] [Abstract][Full Text] [Related]
5. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency]. An N; Li X; Shen M; Chen SL; Huang ZX Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436 [No Abstract] [Full Text] [Related]
6. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure]. Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Scheid C; Sonneveld P; Schmidt-Wolf IG; van der Holt B; el Jarari L; Bertsch U; Salwender H; Zweegman S; Blau IW; Vellenga E; Weisel K; Pfreundschuh M; Jie KS; Neben K; van de Velde H; Duehrsen U; Schaafsma MR; Lindemann W; Kersten MJ; Peter N; Hänel M; Croockewit S; Martin H; Wittebol S; Bos GM; van Marwijk-Kooy M; Wijermans P; Goldschmidt H; Lokhorst HM Haematologica; 2014 Jan; 99(1):148-54. PubMed ID: 23996482 [TBL] [Abstract][Full Text] [Related]
8. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386 [TBL] [Abstract][Full Text] [Related]
9. Current therapy of myeloma induced renal failure. Gertz MA Leuk Lymphoma; 2008 May; 49(5):833-4. PubMed ID: 18452070 [No Abstract] [Full Text] [Related]
10. Pathogenesis and treatment of renal failure in multiple myeloma. Dimopoulos MA; Kastritis E; Rosinol L; Bladé J; Ludwig H Leukemia; 2008 Aug; 22(8):1485-93. PubMed ID: 18528426 [TBL] [Abstract][Full Text] [Related]
11. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695 [TBL] [Abstract][Full Text] [Related]
12. Current treatments for renal failure due to multiple myeloma. Kastritis E; Terpos E; Dimopoulos MA Expert Opin Pharmacother; 2013 Aug; 14(11):1477-95. PubMed ID: 23705905 [TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563 [TBL] [Abstract][Full Text] [Related]
14. [Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy]. Xu Y; An G; Deng SH; Sui WW; Feng XY; Li F; Hao M; Wang YF; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):304-8. PubMed ID: 23668201 [TBL] [Abstract][Full Text] [Related]
15. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? Piro E; Molica S Acta Haematol; 2011; 126(3):163-8. PubMed ID: 21778706 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Nozza A; Siracusano L; Armando S Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177 [TBL] [Abstract][Full Text] [Related]
17. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Kastritis E; Anagnostopoulos A; Roussou M; Gika D; Matsouka C; Barmparousi D; Grapsa I; Psimenou E; Bamias A; Dimopoulos MA Haematologica; 2007 Apr; 92(4):546-9. PubMed ID: 17488666 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib in the front-line treatment of multiple myeloma. Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451 [TBL] [Abstract][Full Text] [Related]
19. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Bladé J; Cibeira MT; Rosiñol L Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]